Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

GRTS
Gritstone bio, Inc. Common Stock
stock NASDAQ

Inactive
Oct 21, 2024
0.0322USD-31.780%(-0.0150)61,017,882
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD-100.000%(-0.05)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
04:05PM EST  Gritstone Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Jan 13, 2022
11:47AM EST  The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact   Benzinga
11:44AM EST  Gritstone Announces First Patient Enrolled For Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE For First Line (1L) Maintenance Treatment Of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)   Benzinga
07:00AM EST  Gritstone Announces First Patient Enrolled for Phase 2/3 Trial   GlobeNewswire Inc
Jan 4, 2022
02:41PM EST  Mid-Afternoon Market Update: Dow Jumps 250 Points; Avrobio Shares Slide   Benzinga
12:17PM EST  Mid-Day Market Update: Nasdaq Dips 250 Points; TherapeuticsMD Shares Surge   Benzinga
10:10AM EST  Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Drops To 58.7   Benzinga
07:04AM EST  UPDATE: Gritstone Says 'Single 10 g dose of samRNA vaccine containing Spike plus additional T cell epitopes (TCE) induced robust neutralizing antibody titers in ten healthy adults 60yrs who had received two prior doses of AstraZeneca's COVID-19 vaccine'   Benzinga
07:04AM EST  Gritstone Announces Clinical Results From First Cohort Of Phase 1 Study Evaluating T Cell-Enhanced samRNA Vaccine Against COVID-19   Benzinga
07:00AM EST  -- Single 10 g dose of samRNA vaccine containing Spike plus additional T cell epitopes (TCE) induced robust neutralizing antibody titers in ten healthy adults 60yrs who had received two prior doses of AstraZenecas COVID-19 vaccine --   GlobeNewswire Inc
Dec 30, 2021
07:00AM EST  Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in the following upcoming investor conferences in January.   GlobeNewswire Inc
Dec 17, 2021
07:00AM EST  -- Clare Fisher, accomplished corporate and business development executive and current svp of business development and mergers & acquisitions at BeiGene, will join the Board effective January 1, 2022 --   GlobeNewswire Inc
Dec 13, 2021
04:05PM EST  Gritstone Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
07:18AM EST  Gritstone bio Announces It Has Been Added To The NASDAQ Biotech Index, Effective Prior To Market Open On Monday, December 20, 2021   Benzinga
07:00AM EST  Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.   GlobeNewswire Inc
Dec 9, 2021
08:41AM EST  Direxion Launches mRNA ETF (MSGR)   PR Newswire
Dec 6, 2021
09:33AM EST  Gritstone bio, CEPI Expand COVID-19 Vaccine Agreement to Combat Omicron Variant   Benzinga
07:12AM EST  Gritstone bio And CEPI Expand Vaccine Agreement In Order To Support The Development Of A Self-amplifying mRNA Vaccine Designed To Tackle The Omicron COVID-19 Variant   Benzinga
07:00AM EST  Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron   GlobeNewswire Inc
Nov 30, 2021
04:03PM EST  Gritstone Says Omicron Mutations Minimally Impact T-Cell Epitope Sequences In Its COVID-19 Vaccines   Benzinga
Nov 29, 2021
07:07AM EST  The Omicron Variant Of SARS-CoV-2 Has Minimal Impact On The T Cell Epitopes Contained Within Gritstone's Self-Amplifying mRNA COVID-19 Vaccines   Benzinga
07:00AM EST  Omicron mutations, while impacting Spike substantially, have minimal impact (~2%) on the T Cell Epitope (TCE) sequences included within Gritstones COVID-19 vaccines (CORAL program)   GlobeNewswire Inc
Nov 23, 2021
04:05PM EST  Gritstone Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Nov 10, 2021
07:07AM EST  Gritstone Announces Preclinical Data In Non-Human Primate Challenge Study With Second-Generation COVID-19 Vaccine Against SARS-CoV-2   Benzinga
07:00AM EST  Self-amplifying mRNA (SAM) vaccination protected against SARS-CoV-2 challenge as both a 2-dose regimen and as a single boost following ChAd prime in rhesus macaques   GlobeNewswire Inc
Nov 4, 2021
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
Nov 3, 2021
06:17PM EDT  Gritstone Oncology Q3 EPS $(0.36) Up From $(0.69) YoY, Sales $2.61M Up From $939.00K YoY   Benzinga
Oct 25, 2021
04:01PM EDT  Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in five upcoming investor conferences in October, November and December.   GlobeNewswire Inc
Sep 24, 2021
04:05PM EDT  Gritstone Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Sep 20, 2021
07:29AM EDT  Biotechnology company Gritstone bio, Inc. (GRTS) announced Monday that the first volunteer has been dosed in a Phase 1 trial evaluating the ability of GRT-R910, a self-amplifying mRNA (SAM) second generation SARS-CoV-2 vaccine to boost and expand the immunogenicity of first-generation COVID-19 vaccines in subjects 60 years of age or older.   RTTNews
07:06AM EDT  Gritstone Doses First Volunteer Phase 1 Trial Of GRT-R910 As COVID-19 Vaccine Booster   RTTNews
07:03AM EDT  Gritstone Announces Dosing Of First Volunteer In Trial Evaluating Self-Amplifying mRNA As A COVID-19 Vaccine Booster And Immunogenicity Enhancer   Benzinga
07:01AM EDT  GRT-R910, a self-amplifying mRNA (SAM) SARS-CoV-2 vaccine, delivers antigens from both the spike protein and highly conserved non-spike proteins for broad protection across variants   GlobeNewswire Inc
Sep 17, 2021
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
07:03AM EDT  Gristone Reports Clinical Data With GRANITE During European Society Of Medical Oncology, Launch Of Randomized Clinical Trial Program For Colorectal Cancer With Registrational Intent   Benzinga
07:02AM EDT  Gritstone Announces Dosing of First Solid Tumor Patient with   GlobeNewswire Inc
07:01AM EDT  Gritstone Announces Positive Clinical Data with GRANITE   GlobeNewswire Inc
Sep 16, 2021
04:02PM EDT  Gritstone Announces 5M Share Private Placement Financing Priced At $11/Share   Benzinga
04:01PM EDT  Gritstone Announces Private Placement Financing of $55.0 Million   GlobeNewswire Inc
Sep 12, 2021
04:04PM EDT  The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs   Benzinga
Sep 9, 2021
04:05PM EDT  Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that it will host a data update webcast for investors and analysts during the European Society of Medical Oncology (ESMO) Annual Meeting 2021, September 17, 2021 at 1:30 p.m. ET.   GlobeNewswire Inc
Sep 7, 2021
04:00PM EDT  Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will present webcasted company overviews at two upcoming investor conferences in September.   GlobeNewswire Inc
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
08:21AM EDT  Gritstone bio, Inc. (GRTS) on Tuesday said it has entered into a funding deal of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance Gritstone's second-generation Covid-19 vaccine program against SARS-CoV-2 Variants.   RTTNews
07:20AM EDT  Gritstone Bio Enters Funding Deal Of Up To $20.6 Mln With CEPI To Advance Development Of CORAL COVID-19 Vaccine Program   RTTNews
07:03AM EDT  Gritstone Bio Enters Up To $20.6M Funding Agreement With Coalition For Epidemic Preparedness Innovations To Advance Gritstone's CORAL COVID-19 Vaccine Program   Benzinga
07:00AM EDT  Gritstone and CEPI Announce Agreement to Advance Second-Generation   GlobeNewswire Inc
Aug 16, 2021
04:00PM EDT  Gritstone Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Aug 11, 2021
07:00AM EDT  Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that it will host a key opinion leader (KOL) webinar on its neoantigen oncology programs for colorectal cancer on Wednesday, August 18, 2021 at 11am Eastern Time.   GlobeNewswire Inc
Aug 5, 2021
04:20PM EDT  Gritstone Oncology Q2 EPS $(0.33) Up From $(0.69) YoY   Benzinga
Aug 4, 2021
07:45AM EDT  Cramer Advises Viewers On Palantir, SoFi And More   Benzinga
Jul 15, 2021
04:00PM EDT  Gritstone Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Jun 23, 2021
08:22AM EDT  Gritstone Names Celia Economides As CFO   Benzinga
08:00AM EDT  Gritstone Announces Management Changes, Including   GlobeNewswire Inc
Jun 17, 2021
08:00AM EDT  Gritstone Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Jun 7, 2021
08:00AM EDT  Gritstone to Present at the Goldman Sachs 42nd Annual Global   GlobeNewswire Inc
Jun 1, 2021
08:00AM EDT  Gritstone Announces Changes to Its Board of Directors   GlobeNewswire Inc
May 24, 2021
04:00PM EDT  Gritstone Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
May 6, 2021
09:11AM EDT  Gritstone Oncology Q1 EPS $0.10 Up From $(0.71) YoY, Sales $39.69M Up From $1.26M YoY   Benzinga
09:01AM EDT  Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the first quarter ended March 31, 2021 and reviewed business highlights.   GlobeNewswire Inc
May 3, 2021
08:00AM EDT  Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced it is changing its name to Gritstone bio, Inc. effective immediately.   GlobeNewswire Inc
Mar 31, 2021
12:11PM EDT  Seeing Gritstone Oncology Block Trade Of ~598.5K Shares At $9.35/Share   Benzinga
Mar 29, 2021
07:01AM EDT  Gritstone Announces First Person Dosed With its Second-Generation COVID-19 Vaccine In Phase 1 Study Conducted And Supported By NIAID/IDCRC   Benzinga
Mar 11, 2021
09:07AM EST  Gritstone Oncology Q4 Net Loss $27.2M vs Net Loss $27.7M In Same Qtr. Last Year, Sales $900.00K Up From $884.00K YoY   Benzinga
09:01AM EST  Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2020 and reviewed business highlights.   GlobeNewswire Inc
Mar 8, 2021
08:46AM EST  Gritstone Announces Promotions Within its Leadership Team   GlobeNewswire Inc
Mar 2, 2021
08:00AM EST  Gritstone to Present at the H.C. Wainwright Global Life Sciences   GlobeNewswire Inc
Feb 1, 2021
01:10PM EST  Gritstone Oncology shares were trading higher after the company announced a deal with Gilead in which Gritstone's vaccine platform will be used for an HIV cure.   Benzinga
06:15AM EST  Gilead Sciences, Inc. (GILD) and Gritstone Oncology, Inc. (GRTS) have entered into a collaboration, option and license agreement. The companies will develop an HIV-specific therapeutic vaccine using Gritstone's prime-boost vaccine platform, with antigens developed by Gilead.   RTTNews
06:05AM EST  Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone's Vaccine Platform Technology for HIV Cure; Gilead Will Make A $60M Payment At Closing   Benzinga
06:03AM EST  Gilead, Gritstone Collaborate Utilizing Vaccine Platform Technology For HIV Cure   RTTNews
06:00AM EST  Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone's Vaccine Platform Technology for HIV Cure   Business Wire
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
10:19AM EST  Mid-Morning Market Update: Markets Open Higher; Morgan Stanley Beats Q4 Expectations   Benzinga
10:12AM EST  Gritstone Oncology shares were trading lower after Baird downgraded the stock from Outperform to Underperform and announced a price target of $8 per share.   Benzinga
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2021   Benzinga
09:56AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
08:01AM EST  Gritstone And Genevant Sciences Announce License Agreement For COVID-19 Vaccine; Genevant Eligible For Up To $192M In Upfront And Contingent Milestone Payments   Benzinga
08:00AM EST  Deal provides nonexclusive accessto Genevants leading LNP technology for use in Gritstones self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in 1Q21   GlobeNewswire Inc
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
06:42AM EST  Baird Downgrades Gritstone Oncology to Underperform, Announces $8 Price Target   Benzinga
06:30AM EST  HC Wainwright & Co. Maintains Buy on Gritstone Oncology, Raises Price Target to $24   Benzinga
Jan 19, 2021
06:08AM EST  Gritstone Advances Second Generation COVID-19 Vaccine CORAL Program With Support From NIAID   RTTNews
06:04AM EST  Gritstone Advances COVID-19 Vaccine 'CORAL' Program with Support From NIAID; Says Phase 1 Clinical Trial Is Expected To Be Conducted Through NIAID-Supported Diseases Clinical Research Consortium   Benzinga
06:00AM EST  Gritstone Advances Second Generation COVID-19 Vaccine   GlobeNewswire Inc
Jan 11, 2021
08:00AM EST  Gritstone Oncology to Present at the 39th Annual J.P. Morgan   GlobeNewswire Inc
Jan 5, 2021
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
Jan 4, 2021
04:39PM EST  Ecor1 Capital Reports 9.99% Passive Stake In Gritstone Oncology   Benzinga
Dec 28, 2020
08:01AM EST  Gritstone Oncology Reports $125M Private Placement   Benzinga
08:00AM EST  --Received Gross Proceeds of $110 Million from Previously Announced PIPE Financing---Executed Additional PIPE Financing of $15 Million--   GlobeNewswire Inc
Dec 23, 2020
08:35AM EST  Gritstone Oncology Reports $110M Private Placement   Benzinga
08:33AM EST  Gritstone Oncology Announces $110 Million Private Placement   GlobeNewswire Inc
Nov 6, 2020
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
Nov 5, 2020
09:07AM EST  Gritstone Oncology Q3 EPS $(0.69) Up From $(0.77) YoY   Benzinga
Nov 2, 2020
08:02AM EST  Gritstone Oncology Begins Dosing Patients in its Phase 2 Expansion Cohorts of the Phase 1/2 Clinical studies for GRANITE and SLATE   Benzinga
08:02AM EST  Gritstone Oncology Advances Into Phase 2 Expansion Cohorts For Its Personalized Neoantigen Immunotherapy GRANITE And Its Off-The-Shelf Neoantigen Immunotherapy SLATE   Benzinga
08:00AM EST  --The Phase 1 portions of the studies are closed for enrollment;patienttreatment and follow-up for efficacy and safety continues--   GlobeNewswire Inc
Sep 15, 2020
08:01AM EDT  Gritstone Oncology Announces Updated Presentation Time at Cantor   GlobeNewswire Inc
Sep 8, 2020
08:00AM EDT  Gritstone Oncology, Inc.(Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a webcasted company overview at two upcoming investor conferences in September.   GlobeNewswire Inc
Aug 5, 2020
09:01AM EDT  Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the second quarter ended June 30, 2020 and reviewed business highlights.   GlobeNewswire Inc
Aug 3, 2020
08:00AM EDT  Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced presentations at two upcoming investor conferences in August.   GlobeNewswire Inc
Jul 14, 2020
07:49AM EDT  BTIG Maintains Buy on Gritstone Oncology, Lowers Price Target to $17   Benzinga
05:11AM EDT  80 Biggest Movers From Yesterday   Benzinga
Jul 13, 2020
02:31PM EDT  Mid-Afternoon Market Update: Dow Jumps 400 Points; Equillium Shares Spike Higher   Benzinga
12:01PM EDT  Mid-Day Market Update: Benefytt Technologies Surges Following Acquisition News; NextCure Shares Slide   Benzinga
10:13AM EDT  Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Estimates   Benzinga
10:04AM EDT  Morning Market Stats in 5 Minutes   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC